Anteris Technologies Global Corp. — Capital/Financing Update 2017

Oct 23, 2017

==> picture [185 x 199] intentionally omitted <==

NEWS RELEASE 24 October 2017

ADMEDUS TAVR PROJECT ON TRACK WITH NEW IP APPLICATIONS

MINNEAPOLIS, MN – Admedus Limited (ASX:AHZ) today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device.

The two separate pending patent applications in the United States relate to the development and manufacture of a three-dimensional replacement heart valve using Admedus’ clinically superior proprietary ADAPT technology that requires minimal suturing; and a hydro-packaging system that will revolutionise the way TAVR products are assembled and distributed.

This marks the beginning of Admedus’ entry into the $3 billion global TAVR market (projected to be $5 billion by 2020) which offers an alternative treatment option for patients who are unsuitable candidates for surgical heart valve replacement or repair.

Both new innovations offer significant improvements in product quality and efficiency as well as reduced manufacturing costs and health benefits to patients.

Admedus has developed a novel process to package and ship the TAVR components in sterile fluid that preserves the integrity of the valve and sterilises the catheter, enabling surgeons to use the product in a more efficient single-step process. The hydro-packaging would allow for the replacement valve and catheter to be supplied in sterile ‘wet packs’ that are ready for immediate use – substantially reducing the time required for assembly preparation.

When manufacturing TAVR devices, one of the most time-consuming and labor-intensive portions of the process is attaching multiple leaflets securely to the stent. Admedus will solve this problem by creating a three dimensional, single-piece molded valve that uses three leaflets in a single scaffold and securely attaches to a stent with minimal sutures.

By reducing the amount of suturing required to attach the valve to the stent 10-fold, Admedus will be able to reduce the cost of manufacturing the TAVR.

“The benefits of our proprietary ADAPT technology and products are now scientifically proven beyond doubt. With published evidence of our durability, and clinically important remodelling and anti-calcification properties and more than nine years of data behind us, we are in a strong competitive position,” said Admedus CEO Wayne Paterson.

==> picture [154 x 11] intentionally omitted <==

==> picture [144 x 30] intentionally omitted <==

“The combination of our 3D valve, hydro-packaging and ADAPT technology would ensure the Admedus TAVR is far superior to any of its competitors – less expensive to produce, more efficient to use and offering greater health benefits to patients. We will not only have unique IP around our valve but also up and down the catheter ensuring a holistic product offering that will bring high value opportunities to the company in the future,” said Paterson.

“This marks an exciting transition in Admedus’ history as the company’s product portfolio moves from a single flat patch product offering one year ago to high value 3D shaped TAVR and SAVR valves and beyond,” added Paterson. “We are now entering an era where we will be providing unique products (such as CardioCel 3D as well as one piece moulded valves) to our physicians and patients that address high unmet medical needs for the future. These and future product entries will position Admedus as a significant player in the multi-billion cardiac device industry as we drive towards becoming a high value bankable company for all stakeholders.”

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Admedus Limited Barb Ferres +61 7 3152 3216 communications@admedus.com

==> picture [154 x 11] intentionally omitted <==